glp-1 patient The Latest on GLP-1s | Lexington Medical Center Blog GLP-1 Receptor Agonists as Treatments
Description
Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial
GLP-1s, first approved for type 2 diabetes in 2005, lower blood glucose, help avoid fatty liver disease, and help with obesity-related problems such as knee pain, sleep apnea, and gastroesophageal reflux
doi: 10.1159/000109998 [DOI] [PMC free article] [PubMed] [Google Scholar] 115
However, the steep costs and unequal access create substantial hurdles
Why the Triple-Agonist Structure Matters Weight loss becomes harder as the body adapts
